ArticleResearch square2026

Itacitinib plus calcineurin inhibitor-based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results.

Nirav Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.